News
DBT supported efficacy trial with recombinant BCG vaccine completes enrolment of 6000 health-workers and high risk individuals
The objective of this trial is to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes of COVID-19 among high-risk persons
.jpeg)
Moderna to expand BARDA agreement to support larger phase 3 program for Covid-19 vaccine
BARDA will extend an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Moderna’s mRNA vaccine candidate (mRNA-1273) against COVID-19.
Delhi’s APAC Biotech bags patent for personalized immunotherapy based cancer treatment
APCEDEN – APAC’s immunotherapy product, has already been approved by the Indian FDA for treating cancer. The company has further announced it will conduct clinical trials for highly aggressive brain tumors
Exhibit in the 'India Pavilion' at BIO 2026
